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Abstract
We are reporting a case of a 55-year-old woman who was diagnosed as having a non-functioning pancreatic neuroendocrine 
neoplasm (NF-PNEN), the World Health Organization (WHO) low grade (G1) with liver metastases. In the staging process the 
positron emission tomography — computed tomography with Fluorine-18-Fluorodeoxyglucose (F-FDG PET-CT) and spiral 
CT then the gallium-DOTA-octreotate positron emission tomography — computer tomography (68Ga-DOTATATE PET-CT) 
shown difference in burden of disease. In first line therapy, everolimus (Afinitor®, Novartis Pharma GmbH, Germany) at the oral 
dose of 10 mg once daily and octreotide long-acting release (Sandostatin LAR®) 30 mg i.m. every 4 weeks were administered. 
Then, due to disease progression — radioisotope therapy with b-emitter Yttrium-90 (90Y). Based on this experience and on 
the review of the literature, we recommend that the discrepancy between the imaging studies could be due to heterogeneity 
of proliferation rate and somatostatin receptors (SSTR) expression within a primary PNEN and metastases. Therefore in such 
cases of advanced PNEN WHO G1 in the lack of response to everolimus and octreotide LAR administration isotope therapy 
without a prior chemotherapy should be considered as a palliative treatment according to ESMO Clinical Practice Guidelines 
and Polish Network of Neuroendocrine Tumors.
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Background
Pancreatic neuroendocrine neoplasms (PNENs WHO 1) are 
rare malignant diseases [1]. Due to frequently asymptomatic 
growth, the majority of PNENs are diagnosed at locally advanced 
or metastatic stage [2]. The role of surgery is therefore often pallia-
tive, whereas chemotherapy has limited activity [3–5]. Recent stud-
ies (RADIANT-2 and RADIANT-3) showed efficacy of everolimus with 
or without concurrent somatostatin analogue in low- or intermediate 
grade advanced PNENs and, therefore, it is recommended in first 
line therapy [6–8]. Everolimus, a 40-O-(2-hydroxyethyl) derivative 
of sirolimus, is an oral inhibitor of mammalian target of rapamycin 
(mTOR), a serine-threonine kinase that stimulates the cell growth, 
proliferation and angiogenesis [9]. So far, it has been used for the 
treatment advanced renal cell carcinoma after failure of treatment 
with sunitinib or sorafenib and in combination with steroidal aro-
matase inhibitor in hormone-receptor positive, human epidermal 
growth factor receptor type 2 (HER2) negative breast cancer, 
after failure of letrozole or anastrozole therapy [10, 11]. The galli-
um-DOTA-octreotate positron emission tomography — computer 
tomography (68Ga-DOTATATE PET) allows visualization of somato-
statin receptors type 2 (SSRT2), typically expressed in intermediate 
and well differentiated primary and metastatic PNENs [12–15], 
while the Positron Emission Computed Tomography PET-CT with 
18F-fluorodeoxyglucose (F-FDG PET-CT) allows detecting sites of 
involvement of poorly differentiated PNENs. 
Case report
A 55-year-old woman was admitted to the hospital in April 
2012 with the head of pancreas tumor seen in triphasic computer 
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tomography (CT) and ultrasonography (USG). At laparotomy the 
tumor was assessed as inoperable; therefore, only duodenochol-
ecystotomy and a tumor biopsy were performed. Pathological report 
showed World Health Organization grade 1 neuroendocrine tumor 
(PNEN WHO G1), neuron specific enolase negative, chromogranin 
weakly positive, synaptophysin strongly positive, Ki67 < 1% cells. 
The F-FDG PET-CT performed on June 19, 2012 showed an ac-
tive metabolic tumor in the head of pancreas with no metastatic 
lesions (Figure 1). Since F-FDG uptake by well-differentiated PN-
ENs is uncommon, two days later an additional 68Ga-DOTATATE 
PET was performed. This examination confirmed the presence of 
the pancreatic tumor (56 x 48 mm), with SSTR expression (SUVmax 
35.4), but additionally revealed numerous liver metastases (15 to 
20 mm; Figure 2). In previous CT, 5 to 7 mm lesions in the liver 
were noted but were not identified as metastases (Figure 3). The 
plasma chromogranin A (pCgA) concentration was in normal 
range. The patient started the treatment with everolimus (Afinitor®, 
Novartis Pharma GmbH, Germany) at the oral dose of 10 mg once 
daily and octreotide long-acting release (Sandostatin LAR®) 30 mg 
i.m. every 4 weeks. Efficacy and safety evaluation included monthly 
clinical examination and laboratory tests, accompanied by chest, 
abdomen and pelvic CT performed every 3 months, using Response 
Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) crite-
ria. A CT scan showed head of the pancreas tumor (52 x 44 mm), 
common bile duct diameter enlarged to 14 mm and 5 to 7 mm liver 
lesions, presumably metastases (Figure 4). During 6-month therapy, 
stable disease (SD) was maintained. Major treatment-adverse 
events included hyperglycemia, neutropenia and elevation of liver 
enzyme levels. In Dec 2012 the everolimus dose was decreased to 
Figure 1. 55-year-old woman with inoperable pancreatic 
neuroendocrine neoplasm (NEN WHO1) The fluorine-18- 
-fluorodeoxyglucose positron emission tomography — computer 
tomography (F-FDG PET-CT), coronal images; an active metabolic 
tumor in the head of pancreas with no liver metastatic lesions 
(Technique: 18F-FDG 285 MBq and 15 ml gastrografin was 
administered, acquisition performed 59 minutes after administration of 
18F-FDG)
Figure 2. 55-year-old woman with inoperable pancreatic 
neuroendocrine neoplasm (NEN WHO1) The gallium-DOTA-
octreotate (68Ga-DOTATATE) PET-CT, coronal images; the presence 
of the pancreatic tumor (56 x 48 mm), with somatostatin receptors 
expression (SSTR, SUVmax 35.4) and numerous liver metastases (15 
to 20 mm). Technique: 68Ga-DOTATATE 115 MBq was administered; 
acquisition performed 60 minutes after administration
Figure 3. 55-year-old woman with inoperable pancreatic 
neuroendocrine tumor (NEN WHO1). The 64-slice computer 
tomography the presence of the pancreatic tumor (52 x 43 mm) and 
hypodense single lesions, the diameter 5 x 5 mm in liver suspected for 
metastases (Contrast enhanced CT, taken with intravenous contrast 
medium — Omnipaque 350/100 ml; axial slice)
Nuclear Medicine Review 2016, Vol. 19, No. 1
www.nmr.viamedica.pl56
Case  
report
5 mg and on March 8, 2013 therapy was stopped after grade 3 com-
mon terminology criteria for adverse events (CTCAE) v.3.0 toxicity, 
including increased levels of alanine aminotransferase (ALT) and as-
partate transaminase (AST). The levels of alanine phosphatase and 
lactate dehydrogenase were slightly elevated (grade 1–2 CTCAE), 
and bilirubin level was within normal range. The hepatitis virus (B, C) 
or cytomegalovirus infection were excluded. The abdominal CT 
and USG showed no evidence of progression. On March 26, 2013 
endoscopic retrograde cholangiopancreatography (ERCP) with 
sphincterotomy and WallflexÒ bile duct stent insertion was per-
formed. Since ALT and AST levels decreased and CT scans did not 
show disease progression, the reinstitution of everolimus at a dose 
of 5 of mg daily was considered. Before restarting therapy, on April, 
2013 second PET-CT using 68Ga-DOTATATE was done and revealed 
progression of the liver metastases: more intensive uptake in the 
existing and new lesions (Figure 5). The everolimus treatment did 
not restart and the patient was referred to radioisotope therapy. 
Between June 2013 and March 2014 she received four b-emitter 
Yttrium-90 (90Y) courses with octreotide long-acting release continu-
ation and disease stabilization was achieved over eleven months. 
She died on February 2015 due to disease progression of the liver 
metastases with high pCgA concentration.
Discussion
The classification and nomenclature of the neuroendocrine 
gastroenteropancreatic neoplasms (GEP NENs) is complex [4, 5]. 
After several modifications, the new WHO classification presented 
in 2010 separating well-differentiated PNENs into low-grade (G1) 
and intermediate grade (G2) categories and all poorly differentiated 
as neuroendocrine carcinoma (PNEC G3) [16]. This classification 
is based on histologic grading system using either mitotic count-
ing or Ki67 labeling index. Nearly one-half of GEP NENs have 
a high heterogeneity of proliferation rate within a tumor (or among 
different sites of disease if metastases are present) [17]. There-
fore, in order to better predict patient outcome, at least 40 high 
power fields should be counted for mitoses and/or Ki67 labeling 
index [17, 18]. Moreover, GEP NETs characterized by heterogeneity 
in the SSTR expression [19, 20]. The SSTR2 is most common in 
PNENs and therefore is used in the diagnosis and treatment [4, 5]. 
For obvious reasons, the proper diagnosis is more difficult if 
is based on material from core needle biopsy.
The use of everolimus vs. best supportive care in advanced 
PNENs (low- or intermediate grade) resulted in impressive increase 
of median progression free survival (11.4 vs 5.4 months, respec-
tively); even though in most patients only disease stabilization or 
minor tumor shrinkage was achieved [8]. In that study, the treatment 
response was assessed by triphasic CT or magnetic resonance 
imaging every 12 weeks according RECIST 1.0 criteria, and all 
discrepancies between local and central assessments were verified 
by independent central adjudication board. However, recent data 
suggest that the RECIST criteria based on measurement of the 
longest diameter of all measurable lesions seen on axial CT may 
be suboptimal in assessing the therapy response in PNENs [21]. 
Similarly, F-FDG PET-CT may be ineffective for PNENs imaging, 
as typically only poorly differentiated, highly malignant PNENs show 
an increased FDG uptake [22]. Interestingly, in our case F-FDG PET 
showed an uptake in the pancreatic tumor despite its low grade, 
whilst metastatic lesions in the liver were not visible. It may be due 
to the above-mentioned SSRT2 expression and proliferation he-
terogeneity within a tumor or among metastases sites. 
68Ga-DOTATATE PET allows visualization of SSTR2, typically 
expressed in the intermediate and well differentiated primary and 
metastatic PNENs [12–15]. This method seems to be more sensitive 
Figure 4. 55-year-old woman with inoperable pancreatic 
neuroendocrine tumor (NEN WHO1). The 64-slice computer 
tomography the presence of the pancreatic tumor (51 x 42 mm) and 
hypodense single lesions, the diameter 7 x 7 mm in liver suspected for 
metastases (Contrast enhanced CT, taken with intravenous contrast 
medium — Omnipaque 350/100 ml; axial slice)
Figure 5. 55-year-old woman with inoperable pancreatic 
neuroendocrine neoplasm (NEN WHO1). The gallium-DOTA-octreotate 
(68Ga-DOTATATE) PET-CT, coronal images; the progression of the 
liver metastases: more intensive uptake in the existing and new lesions
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than F-FDG PET-CT and magnetic resonance imaging in the initial 
staging of PNENs, response evaluation and follow-up [23,  24]. 
In our case, 68Ga-DOTATATE PET allowed early detection of tumor 
progression in the liver. 
Conclusions
The discrepancy between 68Ga-DOTATATE PET, F-FDG PET-CT 
and CT imaging suggests the heterogeneity of proliferation 
and SSRT2 expression in PNENs. It seems that in such a case 
— advanced PNEN G1 in the lack of response to everolimus and 
octreotide LAR administration, isotope therapy without a prior 
chemotherapy should be considered as a palliative treatment ac-
cording to ESMO Clinical Practice Guidelines and Polish Network 
of Neuroendocrine Tumors [4, 5]. The role of 68Ga-DOTATATE PET 
in response assessment during PNENs treatment including everoli-
mus therapy needs to be further determined. Further, so far there 
is no data regarding the relationship between SSTR2 expression 
and response to everolimus therapy.
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